Julie DiCarlo
Keine laufenden Positionen mehr
Profil
Julie DiCarlo worked as the Senior Director of Corporate Communications at Cubist Pharmaceuticals LLC.
She then served as the Head of Investor & Media Relations at Epizyme, Inc. Following that, she held the position of Senior VP of Investor Relations & Communications at PureTech Health Plc.
Lastly, she worked as the Senior Vice President and Head of Communications at Akili, Inc. Ms. DiCarlo completed her undergraduate degree at Towson University.
Ehemalige bekannte Positionen von Julie DiCarlo
| Unternehmen | Position | Ende |
|---|---|---|
| AKILI, INC. | Public Communications Contact | - |
| PURETECH HEALTH PLC | Investor Relations Kontakt | - |
| EPIZYME, INC. | Investor Relations Kontakt | - |
| CUBIST PHARMACEUTICALS INC | Public Communications Contact | - |
Ausbildung von Julie DiCarlo
| Towson University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PURETECH HEALTH PLC | Health Technology |
| AKILI, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
